US biopharma AbbVie to buy Botox maker Allergan for $63 bn ...

US biopharmaceutical company AbbVie said Tuesday it would buy Botox-maker Allergan for about $63 billion, moving to diversify its product line as the ...

Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal

The drugmaker AbbVie said on Tuesday that it planned to buy Allergan, the maker of Botox, for about $63 billion, in one of the biggest mergers in the health ...

Botox maker Allergan bought by US drug giant for $63bn

The US drug company AbbVie is to buy Allergan, the Irish-based maker of Botox, for $63bn (£49bn), in one of the biggest deals in the global pharmaceutical ...

AbbVie to buy Botox maker Allergan for $63B - MedCity News

Chicago-based AbbVie said Tuesday it would acquire Ireland-headquartered Allergan for $63 billion, or $78.45 per share, equal to the former's ...

AbbVie makes $63B bid for Botox maker Allergan | AP News

Facing competition for the world's top-selling drug, AbbVie will spend about $63 billion to buy Botox maker Allergan as it attempts to spur ...

AbbVie looks beyond Humira with $63 billion deal for Botox-maker ...

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle ...

AbbVie to acquire Botox maker Allergan for $63bn - Financial Times

US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a $63bn deal that is the sector's latest blockbuster transaction.

AbbVie, Allergan score FTC approval for $63B merger with one final ...

The partners face just one final hurdle to consummating their $63 billion deal, which would create the fourth-largest drugmaker in the world and ...

AbbVie to Purchase Botox Maker Allergan in $63 Billion Deal

Jun.25 -- AbbVie Inc. agreed to buy Allergan Plc in a $63 billion deal that unites the rival drug makers in a bid for growth.

AbbVie to buy Botox maker Allergan for $63 billion - CBS News

AbbVie said it will buy Allergan for $63 billion, a move designed to diversify AbbVie's drug lineup before Humira, its blockbuster immune disorder treatment, ...

US: AbbVie to Buy Allergan for $63B - PYMNTS.com

US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a US$63 billion that is the sector's latest ...

Abbvie Drops by a Record as Allergan Deal Fails to End Doubts

AbbVie Inc. agreed to pay $63 billion for rival drugmaker Allergan ... order to appease regulators at the U.S. Federal Trade Commission.

AbbVie buying Allergan in $63B deal for its post-Humira future

AbbVie on Tuesday announced it will acquire Allergan in a $63 billion deal, delivering a forceful answer to growing shareholder questions ...

Abbvie to buy Allergan in $63bn deal - Financier Worldwide

Drug manufacturer Abbvie Inc is to acquire Irish rival Allergan Plc for around $63bn in a cash and stock transaction.

Biopharma firm to buy Botox manufacturer for $63B - DrBicuspid.com

AbbVie will acquire Allergan for about $63 billion in cash and stock, according to the companies. The purchase is expected to close in early 2020. Botox is ...

AbbVie to buy Allergan in $63 billion drug deal | CNN Business

AbbVie announced it will buy Allergan for $63 billion, combining the companies behind Humira and Botox and creating yet another pharmaceutical behemoth.

AbbVie to Buy Allergan for $63 Billion - CHEManager

In a deal expected to close early next year, US biopharma AbbVie is buying troubled Botox manufacturer Allergan for $63 billion in cash and ...

Allergan Stock Soars As AbbVie Plans $63 Billion Takeover

Pharma Buying Spree Continues As AbbVie Takes Out Allergan For $63 Billion ... AbbVie (ABBV) is buying Botox-maker Allergan (AGN) in a $63 billion ...

AbbVie deal may conclude a tumultuous 4 years for Botox-maker ...

AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky ...

What the $63 Billion AbbVie Allergan Deal Says About Pharma

AbbVie will buy Botox maker Allergan in a deal valued at about $63 billion. Here's what that says about the state of big drug makers.